SCHEMBL4092170

SCHEMBL4092170

CC(C)(C)c1ccc2c(N3CCCC3)nc(Nc3ccc(F)cc3F)nc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 2/20 0.45
HRH3 Q9Y5N1 2/20 0.45
MAPK14 Q16539 2/20 0.43
EGFR P00533 1/20 0.42
LMNA P02545 5/20 0.39
MAPT P10636 5/20 0.39
KMT2A Q03164 3/20 0.39
HTT P42858 3/20 0.39
NPSR1 Q6W5P4 3/20 0.39
HPGD P15428 2/20 0.39
POLB P06746 2/20 0.39
TSHR P16473 2/20 0.39
MAPK1 P28482 2/20 0.39
MEN1 O00255 2/20 0.39
RECQL P46063 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
APP P05067 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4090388 0.83 LMNA (0.47) HRH4HRH3LMNAMAPTKMT2A
SCHEMBL4084773 0.79 LMNA (0.58) HRH4HRH3EGFRLMNAMAPT
SCHEMBL4095460 0.75 PAK4 (0.47) HRH4HRH3EGFRLMNAMAPT
SCHEMBL4100471 0.72 HRH4 (0.56) HRH4HRH3KMT2AHPGDTSHR
SCHEMBL4095286 0.68 MAPT (0.54) LMNAMAPTKMT2AHTTNPSR1
SCHEMBL17110585 0.66 APP (0.55) MAPK14LMNAMAPTHTTPOLB
SCHEMBL30482729 0.65 NTRK1 (0.75)
SCHEMBL4085159 0.64 KMT2A (0.49) LMNAMAPTKMT2AHTTNPSR1
SCHEMBL5486783 0.64 KMT2A (0.51) LMNAMAPTKMT2AHTTNPSR1
SCHEMBL7836571 0.63 ALDH1A1 (0.51) MAPTKMT2AHTTNPSR1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 HRH4 14/4885HRH3 38/4885MAPK14 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.